We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$47M
Cap. Flow
+$57.5M
Cap. Flow %
7.86%
Top 10 Hldgs %
70.9%
Holding
29
New
3
Increased
6
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$61.4M
2
VRDN icon
Viridian Therapeutics
VRDN
+$34.2M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20M
4
RLMD icon
Relmada Therapeutics
RLMD
+$19.6M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.3M

Top Sells

Rank Stock Value
1
ALT icon
Altimmune
ALT
+$43M
2
CGEM icon
Cullinan Oncology
CGEM
+$15.9M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$14.9M
4
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$14.8M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
26
Corvus Pharmaceuticals
CRVS
$1.12B
$603K 0.08%
250,000
-3,177,461
-93% -$12.3M
ALT icon
27
Altimmune
ALT
$552M
– –
-3,800,000
Closed -$43M
CGEM icon
28
Cullinan Oncology
CGEM
$1.01B
– –
-706,050
Closed -$15.9M
PHVS icon
29
Pharvaris
PHVS
$2.28B
– –
-552,882
Closed -$9.8M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q4 2021 Portfolio in Review

As of Q4 2021, VR Adviser held 29 positions worth $732M, down 6% from $779M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

VR Adviser deployed $57.5M of net new capital in Q4 2021, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was LianBio American Depositary Shares: 5,378,341 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Olema Pharmaceuticals, an estimated $14.9M trimmed.

  • VR Adviser's largest Q4 2021 buy was LianBio American Depositary Shares: 5,378,341 shares worth $33.1M.
  • VR Adviser added most to Viridian Therapeutics in Q4 2021, an estimated $34.2M increase.
  • VR Adviser's biggest Q4 2021 reduction was Olema Pharmaceuticals, cutting an estimated $14.9M.
  • VR Adviser fully exited Altimmune in Q4 2021, selling an estimated $43M.
  • VR Adviser's ten largest holdings make up 71% of its $732M portfolio in Q4 2021.
  • VR Adviser opened 3 new positions and closed 3 in Q4 2021.
  • VR Adviser's portfolio value fell 6% quarter-over-quarter to $732M.

Based on VR Adviser's 13F filing for Q4 2021, filed 14 Feb 2022.